The HMG-box transcription factor 1/TIMP metallopeptidase inhibitor 3/PTEN axis inhibits the tumorigenesis of breast cancer and promotes the sensitivity of breast cancer to radiotherapy and hormone therapy 30. Here, PTEN is linked to breast carcinoma.